Oppenheimer Reaffirms Their Buy Rating on Cue Biopharma (CUE)

Cue Biopharma GAAP EPS of -$0.25 beats by $0.03, revenue of $1.7M beats by $0.49M

Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights

Insmed (INSM) Reports Q1 Loss, Lags Revenue Estimates

Cue Biopharma to Present at the 20th Annual PEGS Boston Summit

Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference

Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference

Here's Why Cue Biopharma (CUE) is Poised for a Turnaround After Losing -22.83% in 4 Weeks

Here's Why Cue Biopharma (CUE) is Poised for a Turnaround After Losing -22.83% in 4 Weeks

Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now

Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now

Cue Biopharma: A Strong Buy on Clinical Breakthroughs and Strategic Financial Positioning

Cue Biopharma: A Strong Buy on Clinical Breakthroughs and Strategic Financial Positioning

Oppenheimer Remains a Buy on Cue Biopharma (CUE)

Oppenheimer Remains a Buy on Cue Biopharma (CUE)

Cue Biopharma (CUE) Gets a Buy from Stifel Nicolaus

Cue Biopharma (CUE) Gets a Buy from Stifel Nicolaus

Cue Biopharma (CUE) Gets a Buy from Piper Sandler